Cancer Drug Shortages Threaten Lives as Efforts to Prevent Them Hit Regulatory Red Tape
核心洞察
Persistent shortages of inexpensive generic injectable cancer drugs are disrupting treatment for pediatric and adult oncology patients, with seven oncology drugs currently listed in short supply by the FDA.
Ifosfamide, a critical agent for bone and soft tissue tumors (搜索) and lymphoma (搜索), entered expected shortage until next year after a German manufacturer halted production following an FDA warning letter citing contamination and microbial growth.
Domestic manufacturers such as Cost Plus Drugs (搜索) face nearly $360,000 in FDA filing fees to produce ifosfamide, a barrier that could be removed through a fee waiver or executive order.
Persistent shortages of inexpensive, generic injectable cancer drugs continue to threaten the lives of patients across the United States, including children with cancer, as efforts to shore up the domestic supply chain collide with regulatory and financial barriers. A review of the FDA's shortage list shows seven oncology drugs currently in short supply, a situation that forces clinicians to make difficult treatment decisions and leaves families scrambling to secure life-saving medications.
The human toll of these shortages is exemplified by Abby Bray, a childhood cancer survivor who was diagnosed with leukemia (搜索) just after her ninth birthday. During her years of treatment, doctors repeatedly lost her treatment plan because the drugs she needed were in short supply. Her mother, Laura Bray, recalled her then-9-year-old daughter asking what would happen if the drugs were not available: "Do I die?" Abby described the experience as "almost a dooming feeling," adding, "Like, what happens if I don't get this?"
Ifosfamide Shortage Disrupts Oncology Care
Among the oncology drugs currently in short supply is ifosfamide, a critical cancer drug used for bone and soft tissue tumors (搜索) and lymphoma (搜索). Dr. Pinki Prasad, a pediatric oncologist in Louisiana, relies on the agent and said the shortage is directly affecting treatment decisions.
"You're having to make decisions about if, I start somebody on this therapy and in two weeks they're due again, will they be able to get it?" Dr. Prasad said. She emphasized that there is no simple substitute to use in its place, stating, "This is our reality, but it's not fair."
Drug shortages typically do not arise simply from increased demand or a lack of ingredients; they stem from serious quality issues. This spring, a key maker of ifosfamide in Germany had to temporarily halt production after a scathing warning letter from the FDA, which said its drugs were "adulterated," citing contamination and microbial growth. The resulting supply chain disruption was serious enough to place ifosfamide into expected shortage until next year.
Barriers to Domestic Manufacturing
The question of why critical drugs are not simply manufactured domestically led to Dr. Alex Oshmyansky, CEO of Cost Plus Drugs (搜索), who has made it his mission to fill supply gaps. "For someone in our country not to be able to get access to a medicine that costs $10, $20 to save their life. It's just absolutely insane," he said.
Cost Plus is working to make ifosfamide, but is only permitted to do so while the drug is officially in shortage; once it is removed from the list, production stops. "To prevent the shortage before it's happening and make the drug, that's a much more expensive process," Oshmyansky said.
A central obstacle is financial. If Cost Plus wanted to begin making ifosfamide outright, it would have to pay nearly $360,000 in FDA filing fees, making it difficult for U.S. manufacturers to operate in the black on inexpensive yet essential generic drugs. The FDA could waive those fees, but when asked whether it would, the agency offered no response. Oshmyansky indicated that the President could act through an executive order to cut through the red tape: "If that fee could be waived for drugs produced in the United States, we'd get up and running and start making a lot of these products right away."
Reliance on Foreign Manufacturers
With U.S. drugmakers describing themselves as handcuffed by financial reality, the FDA reportedly considered drug makers in India to fill the ifosfamide gap. The frontrunners were companies previously investigated for serious quality control violations identified by the very agency seeking their help. Ultimately, the FDA approved temporary imports of Ifosfamide for Injection currently marketed in China. Critics contend that relying on foreign makers over domestic stability comes down to the bottom line.
Advocacy and the Path Forward
For Abby Bray, now cancer-free, the reliance on profit as a driver is unacceptable. "I feel like profit should not be the main driver in anything you do," she said. Abby received the drugs she needed because her mother, Laura, was relentless, an effort that grew into the nonprofit Angels for Change (搜索). Today, mother and daughter work together to secure drugs for thousands of patients in need.
Nearly seven years later, the organization still refers to the girl at the center of its founding as "Patient one." "Patient one was Abby," Laura said. "And if I'm not willing to do for patient 800,000 of what I did for patient one, then we're missing the mark." Abby added, "I just want every kid to have what they need to keep going."
Abby and Laura Bray are set to appear on Capitol Hill early next year, alongside other patients who have dealt with this issue firsthand, to share their experiences and urge change.